Search
Talmapimod
go.drugbank.com/drugs/DB05412InvestigationalTalmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
Elacridar
go.drugbank.com/drugs/DB04881InvestigationalElacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).
Cefacetrile
go.drugbank.com/drugs/DB01414InvestigationalVet approvedA derivative of 7-aminocephalosporanic acid.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseRoxarsone
go.drugbank.com/drugs/DB11458ExperimentalVet approvedThe drug is also approved in the United States for use in pigs.
iCo-007
go.drugbank.com/drugs/DB05268InvestigationaliCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis
D-Glutamine
go.drugbank.com/drugs/DB02174ExperimentalIt is the principal carrier of nitrogen in the body and is an important energy source for many cells.
Fluciclatide
go.drugbank.com/drugs/DB14842InvestigationalFluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.
AEM-28-14
go.drugbank.com/drugs/DB17643Experimental[L45909] It is being investigated for lipid disorders such as homozygous familial hypercholesterolemia.[L45914]
Elsubrutinib
go.drugbank.com/drugs/DB18850InvestigationalElsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants